Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Importance of Protocol Standards in the Preparation of Breast Sentinel Node Injections.

Journal of nuclear medicine technology·2026
Same author

Simulation-Enhanced Learning in Nuclear Medicine: Theory, Modalities, and Applications Across the Training Continuum.

Journal of nuclear medicine technology·2026
Same author

Simulation-Enhanced Learning in Nuclear Medicine: Practical-Use SCAFFOLD.

Journal of nuclear medicine technology·2026
Same author

LASER: A Phase 2 Trial of <sup>177</sup>Lu-PSMA-617 as Systemic Therapy for RCC.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Impact of <sup>18</sup>F-FDG Vials on Well Counter Background Radiation: Evaluating Shielding and Distance Effects.

Journal of nuclear medicine technology·2025
Same author

Role and Qualifications of Nuclear Medicine Technologists on the Theranostic Team.

Journal of nuclear medicine technology·2025
Same journal

<sup>18</sup>F-NaF PET/CT Versus <sup>18</sup>F-FDG PET/CT for Baseline Mapping in Ollier Disease: A Pediatric Case.

Journal of nuclear medicine technology·2026
Same journal

Incidental Detection of Aggressive HER2-Positive Breast Cancer on <sup>99m</sup>Tc-Sestamibi Parathyroid Scintigraphy.

Journal of nuclear medicine technology·2026
Same journal

Structured Educational Tours in Hospital-Based Radiopharmaceutical Production: Balancing Safety and Learning.

Journal of nuclear medicine technology·2026
Same journal

Development of a Phantom for Evaluating Image Quality and Partial-Volume Effects in Hot and Cold Regions in Small-Animal SPECT and PET.

Journal of nuclear medicine technology·2026
Same journal

Nonuniformity in a Certified <sup>68</sup>Ge PET Cylinder Phantom: Implications for Normalization Quality Assurance.

Journal of nuclear medicine technology·2026
Same journal

Reducing Formation of Suspected Tracer Microemboli During Preparation of <sup>99m</sup>Tc-Tagged Heat-Damaged Red Blood Cells.

Journal of nuclear medicine technology·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prostate Cancer: Staging, Progression, and Treatment.

Nicole LaBrecque1, Alexia Romano2, Jared LeBlanc3

  • 1Dana-Farber Cancer Institute, Boston, Massachusetts.

Journal of Nuclear Medicine Technology
|June 3, 2026
PubMed
Summary
This summary is machine-generated.

Prostate cancer is increasingly diagnosed in younger men, possibly due to increased prostate-specific antigen (PSA) screening. Diagnosis and treatment depend on staging, utilizing tools like PSA levels, imaging, and Gleason scores.

Keywords:
Gleason scorePSMA PET/CTcancer stagingprostate cancerprostate-specific antigenradiopharmaceutical therapy

More Related Videos

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jun 5, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer traditionally affects older men, but recent data indicate a trend towards earlier diagnoses.
  • Increased prostate-specific antigen (PSA) screening may contribute to the rising incidence in younger populations.

Purpose of the Study:

  • To summarize the current understanding of prostate cancer diagnosis and staging, particularly in the context of shifting age demographics.
  • To highlight the role of PSA screening and various diagnostic tools in prostate cancer evaluation.

Main Methods:

  • Review of emerging evidence on prostate cancer incidence trends.
  • Analysis of the diagnostic significance of prostate-specific antigen (PSA) levels.
  • Overview of imaging and assessment tools used for staging prostate cancer.

Main Results:

  • Evidence suggests a shift in prostate cancer diagnosis towards younger age groups.
  • Elevated PSA levels correlate with an increased likelihood of prostate cancer.
  • Staging involves multiple modalities including CT, MRI, bone scans, PSMA PET/CT, and Gleason score.

Conclusions:

  • Prostate cancer management is individualized, based on stage, risk, and patient factors.
  • Accurate staging is crucial for effective prostate cancer diagnosis and treatment planning.
  • A combination of screening, imaging, and pathological assessment is essential for comprehensive prostate cancer care.